Renishaw has a policy of regularly updating its software to fix bugs, add functionality, extend language support, reflect changes in standards and respond to changes in Microsoft software. If you are not using the latest software you could be missing out on these features.

  1. Renishaw.com-Resource centre-Software download: DX10 and device drivers V2.02 64-bit Software download: DX10 and device drivers V2.02 64-bit (zip) File size: 8.92 MB Language: English.
  2. Renishaw is a global company with core skills in measurement, motion control, spectroscopy and precision machining. Corporate responsibility Details of our business code, charities committee and our statement about modern slavery.
  3. The orthopedic 3D printed devices market is poised to grow by $ 1.49 bn during 2020-2024 progressing at a CAGR of 24% during the forecast period. The reports on the orthopedic 3D printed devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25.
  4. The user is cautioned that any changes or modifications not expressly approved by Renishaw plc or authorised representative could void the user’s authority to operate the equipment. This equipment has been tested and found to comply with the limits for a Class A digital device, The packaging of our products contains the following materials.

Current versions of software may not be compatible with all previous versions of hardware or combinations of hardware. If you have any doubts, please contact us.

Renishaw Plc Port Devices Driver
SoftwareVersion numberDownload
CARTO v4.2 SP1Full version Windows 10 compatible only
CARTO v3.8 32bitFull version Windows 7/8 compatible only
CARTO v3.8 64bitFull version Windows 7/8 compatible only
Compensate SiemensActivation license. Contact Renishaw or purchase from the web shop
Compensate LinearActivation license. Contact Renishaw
Ballbar 20 v5.09.09Full version
Ballbar Trace v1.0Full version
Off axis rotary v2.01Contact Renishaw or purchase from the web shop
QuickViewXL v1.0.430 day trial or purchase from the web shop
XK10 display unitv12.11Full version

Calibration system software

・ Control by Bluetooth (Serial Port Profile) Interface notes (must read!) ・ USB connection example Tablet → USB (OTG) cable → USB / RS-232C conversion cable → YAESU CT-62 cable → FT-818. It will not work with a USB cable that does not support OTG. The built-in device of the USB / RS-232C conversion cable supports only FTDI.

  • Software download: Ballbar Trace software v1.0 SP1

Software release notes

Driver

Legacy software

Legacy software has reached ‘end of support'. This means the software can no longer be supported for bug fixes or enhancements. If there is functionality that you believe does not exist within our latest software for a current product, please contact your local Renishaw office.

Renishaw Plc Port Devices Driver

If you are using hardware which is not compatible with our latest software, you may be interested in our upgrade options.

Software Current version numberDownload
LaserXL v20.02.02.01Full version
RotaryXL v1.10Full version
XCal-View v2.4Contact Renishaw or 30 day trial
Renishaw analysis v20.03.02.04Full version
Laser 10 v10.06Full version

Legacy software

Drivers

Renishaw Plc Port Devices Driver

  • Software download: RotaryXL V1.10
  • Software download: Renishaw analysis V20.03.02.04
  • Software download: DyconXL V1.2.0.3
  • Software download: DX10 and device drivers V2.02 64-bit

Software release notes

Added: 16th March 2020 by Renishaw

Global engineering technologies company, Renishaw, announces that its award-winning intraparenchymal drug delivery device, has played a critical role in a joint Phase 1-2 clinical study with Herantis Pharma plc, for the investigation of cerebral dopamine neurotrophic factor (CDNF) as a treatment for Parkinson's disease.

The study's repeated delivery regime, which allows for a prolonged therapeutic window, is crucial to achieve the potential neuroprotective and neurorestorative actions of CDNF, and has been made possible through the use of Renishaw's ground-breaking drug delivery system.

Initial results indicate predictable and accurate placement of the device as well as its positive performance and safety. The Company will continue to assess the results as the data is analysed and through the extension part of the study, as patients receive ongoing monthly infusions of CDNF using the Renishaw device.

Rupert Jones, Managing Director of Renishaw Medical, said, “The results of this trial and the performance of Renishaw's drug delivery system are promising for the many people with Parkinson's disease and I would like to take this opportunity to thank the trial participants for making this possible.”

Renishaw Plc Port Devices Driver

He added, “These results allow us to build towards CE marking of Renishaw's device so that further neurodegenerative and neuro-oncological conditions can benefit from our technology. We see our device as an enabling technology that facilitates the reliable and repeated delivery of therapeutic agents direct to targets deep within the parenchyma, as part of a paradigm shift in the way treatments of neurological disorders and brain tumours are progressing.”

About the device

Renishaw's intermittent drug delivery system comprises of up to four catheters, which can be implanted into target areas within the brain. The catheters are accessed via a 3D printed titanium transcutaneous port implanted behind the patient's ear. Drug-filled infusion lines are connected using an MRI compatible application set, which repeatably locates onto the port. Retractable needles extend through a septum in the port to enable therapeutics in the external infusion lines to be infused through the implanted catheters.

Renishaw Plc Port Devices Driver Windows 7

Thanks to this innovative, patented design, patients are able to receive infusions in an out-patient setting, rather than requiring the reimplantation of new catheters for each infusion, which has been the only option for many trials to date.

About the study

The study was a first-in-human, study whereby 17 patients were randomised to receive either one dose per month for six months, of a placebo, or six increasing doses of Herantis Pharma plc's novel drug candidate, CDNF, over the same period in a blinded manner. After this six month period, patients may enter into an additional six-month study where all participants receive CDNF. In total, patients will receive 12 infusions, all delivered in an out-patient setting.

The primary endpoints evaluate the safety, performance/tolerability of both the drug delivery system and CDNF as well as surgical accuracy. Secondary to this, the potential efficacy of the drug, rated against the Unified Parkinson's Disease Rating Scale (UPDRS) motor score evaluation, was also monitored.

Coments are closed
Scroll to top